Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 31, 2025
DataAggregated Company Financials
Companies567
- 7D-0.4%
- 3M-10.5%
- 1Y-12.5%
- YTD-6.5%
The Biotech is pretty flat in the last 7 days, but Amgen has stood out, gaining 6.1%. As for the longer term, the industry has declined 13% in the last year. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 31 May 2025 | US$930.3b | US$155.8b | -US$23,980,169,264.90 | 15.6x | -38.8x | 6x |
| Mon, 28 Apr 2025 | US$783.2b | US$119.2b | -US$31,074,126,492.82 | 19.8x | -25.2x | 6.6x |
| Wed, 26 Mar 2025 | US$838.8b | US$118.6b | -US$36,983,100,341.21 | 20.2x | -22.7x | 7.1x |
| Fri, 21 Feb 2025 | US$857.3b | US$117.0b | -US$37,500,625,878.71 | 16.9x | -22.9x | 7.3x |
| Sun, 19 Jan 2025 | US$947.4b | US$149.4b | -US$26,286,185,460.05 | 17.3x | -36x | 6.3x |
| Tue, 17 Dec 2024 | US$991.6b | US$150.0b | -US$26,487,519,670.88 | 16.7x | -37.4x | 6.6x |
| Thu, 14 Nov 2024 | US$1.1t | US$150.0b | -US$27,361,732,021.47 | 15x | -39x | 7.1x |
| Sat, 12 Oct 2024 | US$884.5b | US$113.1b | -US$36,028,289,614.54 | 20.6x | -24.6x | 7.8x |
| Mon, 09 Sep 2024 | US$874.9b | US$113.1b | -US$35,665,603,175.32 | 22.2x | -24.5x | 7.7x |
| Wed, 07 Aug 2024 | US$1.2t | US$165.8b | -US$32,869,773,768.90 | 23.9x | -35.3x | 7x |
| Fri, 05 Jul 2024 | US$1.1t | US$164.5b | -US$28,070,736,754.86 | 27.9x | -39.9x | 6.8x |
| Sun, 02 Jun 2024 | US$1.1t | US$164.6b | -US$26,677,143,877.65 | 27.4x | -42.1x | 6.8x |
| Tue, 30 Apr 2024 | US$1.1t | US$164.6b | -US$27,374,440,770.81 | 22.8x | -39.1x | 6.5x |
| Thu, 28 Mar 2024 | US$1.2t | US$164.4b | -US$23,823,048,661.67 | 21.5x | -49.4x | 7.2x |
| Sat, 24 Feb 2024 | US$1.2t | US$166.7b | -US$21,620,417,137.21 | 10.8x | -54.5x | 7.1x |
| Mon, 22 Jan 2024 | US$1.4t | US$204.8b | -US$22,505,807,764.00 | 18.5x | -63.4x | 7x |
| Wed, 20 Dec 2023 | US$1.4t | US$204.8b | -US$22,154,151,632.00 | 19.6x | -61.2x | 6.6x |
| Fri, 17 Nov 2023 | US$1.2t | US$204.7b | -US$22,125,754,712.00 | 16.5x | -54.7x | 5.9x |
| Sun, 15 Oct 2023 | US$1.3t | US$207.3b | -US$13,137,172,262.00 | 16.6x | -96.4x | 6.1x |
| Tue, 12 Sep 2023 | US$1.3t | US$207.6b | -US$12,635,687,518.00 | 17.5x | -101.7x | 6.2x |
| Thu, 10 Aug 2023 | US$1.3t | US$207.7b | -US$12,585,104,613.00 | 16.7x | -101.4x | 6.1x |
| Sat, 08 Jul 2023 | US$1.1t | US$186.3b | -US$16,022,507,026.00 | 12.9x | -69.1x | 5.9x |
| Mon, 05 Jun 2023 | US$1.1t | US$185.9b | -US$16,012,816,022.00 | 11.4x | -71.1x | 6.1x |
| Wed, 03 May 2023 | US$1.2t | US$197.5b | -US$6,736,968,452.00 | 14.4x | -171.8x | 5.9x |
| Fri, 31 Mar 2023 | US$1.1t | US$198.6b | -US$3,738,200,739.00 | 13.9x | -303.7x | 5.7x |
| Sun, 26 Feb 2023 | US$1.1t | US$200.5b | -US$3,797,679,065.00 | 14.2x | -295.4x | 5.6x |
| Tue, 24 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.7x | 665x | 5.7x |
| Thu, 22 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.6x | 711.6x | 5.7x |
| Sat, 19 Nov 2022 | US$1.1t | US$202.2b | US$1.2b | 14.7x | 916.1x | 5.6x |
| Mon, 17 Oct 2022 | US$1.0t | US$206.0b | US$5.4b | 15.6x | 194.3x | 5.1x |
| Wed, 14 Sep 2022 | US$1.1t | US$206.9b | US$5.9b | 15.8x | 185.7x | 5.3x |
| Fri, 12 Aug 2022 | US$1.1t | US$207.0b | US$7.7b | 15.9x | 143.3x | 5.3x |
| Sun, 10 Jul 2022 | US$1.1t | US$211.5b | US$10.8b | 17.4x | 102.3x | 5.2x |
| Tue, 07 Jun 2022 | US$990.4b | US$212.7b | US$11.3b | 16x | 87.8x | 4.7x |
Price to Earnings Ratio
87.8x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.9% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.67% | |
| Healthcare | 1.69% | |
| Biotech | -0.44% | |
| Biotech | -0.44% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AMGN Amgen | US$288.18 | 6.1% +US$8.9b | -5.8% | PE26.1x | |
| ABBV AbbVie | US$186.11 | 1.6% +US$5.0b | 15.4% | PE79.1x | |
| GILD Gilead Sciences | US$110.08 | 2.5% +US$3.4b | 71.3% | PE23x | |
| ALNY Alnylam Pharmaceuticals | US$304.56 | 5.0% +US$1.9b | 105.2% | PS16.9x | |
| VRTX Vertex Pharmaceuticals | US$442.05 | 1.4% +US$1.6b | -2.9% | PS10.2x |
